Fulcrum Therapeutics (NASDAQ:FULC) Issues Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) released its earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31), Zacks reports.

Fulcrum Therapeutics Stock Performance

FULC opened at $10.89 on Tuesday. The company has a market cap of $589.37 million, a price-to-earnings ratio of -9.23 and a beta of 3.19. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $15.74. The business’s fifty day moving average is $10.87 and its two-hundred day moving average is $9.47.

Insider Buying and Selling at Fulcrum Therapeutics

In other news, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. The trade was a 3.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. This represents a 40.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

Several large investors have recently modified their holdings of the business. Algert Global LLC acquired a new stake in shares of Fulcrum Therapeutics during the third quarter valued at $152,000. WINTON GROUP Ltd purchased a new position in Fulcrum Therapeutics in the 3rd quarter valued at about $149,000. Brevan Howard Capital Management LP purchased a new position in Fulcrum Therapeutics in the 3rd quarter valued at about $141,000. Entropy Technologies LP acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth about $136,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Fulcrum Therapeutics by 137.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,274 shares of the company’s stock worth $131,000 after purchasing an additional 8,275 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on FULC. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Stifel Nicolaus set a $25.00 target price on Fulcrum Therapeutics in a report on Monday, December 8th. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an “overweight” rating and a $20.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.11.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.